2nd Quarter - Report

HELIX, INC. for HELIX, INC.

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Oversight of Lab Developed Tests, express legislative authority.

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Budget/Appropriations BUD

Continuing Resolutions and FY24 Budget Viral Surveillance funding, COVID Supplemental allocation retention, general HHS funding, including ASPR, AMD programs.

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Health & Human Services, Dept of (HHS)

Science/Technology SCI

Whole Exome Sequencing, DNA screening testing and diagnostics, access to clinical trials

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.